![]() ![]() ![]() In view of the relatively poorer outcomes and risks of severe toxicity, treatment options for older patients with advanced lung cancer remain a subject of discussion. Lung cancer is one of the most common cancers affecting the older population in Japan the median age at diagnosis is 70 years, and one-third of the patients are over 80 years old. The competing interests stated do not alter our adherence to PLOS ONE policies on sharing data and materials. Shoko Noda-Narita, Asuka Kawachi, and Ryo Sadachi, have nothing to disclose. Kan Yonemori reports personal fees from Novartis, Pfizer, Chugai, Eisai, Taiho, and AstraZeneca, outside the submitted work. Takahiro Higashi is employed by the National Cancer Center Japan, which is responsible for operating hospital-based cancer registries nationwide, during the conduct of the study, and the data collection was funded by the internal grant of National Cancer Center. Yasuhiro Fujiwara reports grants and committee member from Japan Agency for Medical Research and Development, and The Ministry of Health Labor and Welfare, Japan, during the conduct of the study, and lecture fee from Astra Zeneca KK, Daiichi Sankyo Co., Ltd, Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Novartis Pharma KK, SRL Inc, Bristol-Myers Squibb KK, and Santen Pharmaceutical Co., Ltd, outside the submitted work. Yasushi Goto reports grants and personal fees from Eli Lilly, Chugai, Taiho Pharmaceutical, Pfizer, Novartis, MSD, Guardant Health, and Ono Pharmaceutical, and grants from Kyorin, and Dai-ichi Sankyo, and personal fees from Boehringer Ingelheim, AstraZeneca, and Glaxo Smith Kline, outside the submitted work. Akihiro Hirakawa reports grants and personal fees from Ono Pharmaceutical, and personal fees from Astellas Pharma, AbbVie, Nippon Boehringer Ingelheim, Kissei Pharmaceutical, Pfizer, and Nippon Shinyaku, outside the submitted work. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the manuscript and its Supporting Information.įunding: The authors received no specific funding for this work.Ĭompeting interests: I have read journal’s policy and the authors of this manuscript have the following competing interests: Ayako Okuyama reports grants and other from National Cancer Center in Japan, during the conduct of the study. Received: DecemAccepted: SeptemPublished: September 20, 2021Ĭopyright: © 2021 Noda-Narita et al. PLoS ONE 16(9):Įditor: Wen-Chi Chou, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, TAIWAN (2021) First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data. Additionally, patients who were aged ≥ 80 years also received systemic chemotherapy, including platinum doublets age did not solely influence regimen selection.Ĭitation: Noda-Narita S, Kawachi A, Okuyama A, Sadachi R, Hirakawa A, Goto Y, et al. Despite recommendations of Japanese guidelines for NSCLC, 60.7% of those who were aged ≥75 years received platinum doublets. In this study, platinum doublets were identified as the most commonly prescribed regimen in those who were aged ≥ 70 years. Carboplatin was commonly prescribed in all age groups only 28.4% of those receiving platinum doublets selected cisplatin. Patients who were aged ≥ 80 years also preferred platinum doublets (35.6%). Among them, platinum doublets were prescribed for 62.7% of the patients who were aged ≥ 70 years, and 60.7% of the patients who were aged ≥ 75 years with no driver mutations in NSCLC only 37.6% of them received single agents. We found that the proportion of patients receiving chemotherapy decreased with age 80.0%, 70.4%, 50.6%, and 30.2% of patients aged 70–74, 75–79, 80–84, and ≥ 85 years, respectively, received chemotherapy. The first-line chemotherapy regimens among 9,737 patients who were diagnosed with advanced lung cancer between January and December 2013, were identified and compared based on age. Data from the survey database of Diagnostic Procedure Combination and hospital-based cancer registries of designated cancer centers nationwide were used. This study aimed to examine the prescribing patterns of first-line chemotherapy according to age in the real-world practice. In clinical practice, physicians are required to decide the treatment based on a lack of enough evidence. In Japan, single agent chemotherapy was recommended for advanced non-small cell lung cancer (NSCLC) for those, who were aged ≥75 years, while the Western guidelines did not recommend a specific regimen. ![]() Aging of the population has led to an increase in the prevalence of cancer among older adults. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |